Polymorphism in the HMOX1 gene is associated with high levels of fetal hemoglobin in brazilian patients with sickle cell Anemia

Hemoglobin

Volumn 37, Issue 4, 2013, Pages 315-324

  Gil, Gislene P ^a   Ananina, Galina ^a   Oliveira, Mariana B ^a   Costa, Fernando F ^b   Silva, Márcio J ^a   Santos, Magnun N N ^b   Bezerra, Marcos A C ^c   Hatzlhofer, Betânia L D ^c,d   Araujo, Aderson S ^c   Melo, Mônica B ^a  

^a Center of Molecular Biology and Genetic Engineering (CBMEG)   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c Haematology and Haemotherapy Centre of Pernambuco HEMOPE   (Brazil)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Fetal hemoglobin; Heme oxygenase; Oxidative stress; Polymorphism; Sickle cell anemia

Indexed keywords

BIOLOGICAL MARKER; GENOMIC DNA; HEME OXYGENASE 1; HEMOGLOBIN F;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CHILD; DNA EXTRACTION; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRESCHOOL CHILD; SCHOOL CHILD; SEQUENCE ANALYSIS; SICKLE CELL ANEMIA;

ADOLESCENT; ADULT; ALLELES; ANEMIA, SICKLE CELL; BRAZIL; CHILD; FEMALE; FETAL HEMOGLOBIN; GENE FREQUENCY; GENOTYPE; HEME OXYGENASE-1; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 84879835269     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2013.789438     Document Type: Article

References (49)

1. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337(11):762-769.
2. Gonçalves MS, Bomfim GC, Maciel E, et al. ?S-Haplotypes in sickle cell anemia patients from Salvador, Bahia, Northeastern Brazil. Braz J Med Biol Res. 2003;36(10):1283-1288.
3. Zago MA, Costa FF, Bottura C, Ione IG. Hereditary hemoglobin disorders in a Brazilian population. Hum Hered. 1983;33(2):125-129.
4. Zago MA, Costa FF, Freitas TC, Bottura C. Clinical, hematological and genetic features of sickle cell anemia and sickle ?-thalassemia in a Brazilian population. Clin Genet. 1980;18(1):58-64.
5. Salzano FM. Incidence, effects and management of sickle cell disease in Brazil. Am J Pediatr Hematol Oncol. 1985;7(3):240-244.
6. Steinberg MH. Pathophysiology of sickle cell disease. Bailliére's Clin Haematol. 1998;11(1):163-184.
7. Steinberg MH, Adewoye AH. Modifier genes and sickle cell anemia. Curr Opin Hematol. 2006;13 (3):131-136.
8. Adams GT, Snieder H, McKie VC, et al. Genetic risk factors for cerebrovascular disease in children with sickle cell disease: design of a case-control association study and genome wide screen.BMC.Med Genet. 2003;4:6-15.
9. Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118 (1):19-27.
10. Hardison RC, Chui DHK, Giardine B, et al. HbVar: a relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. Hum Mutat. 2002;19(3):225-233 (http://globin. cse.psu.edu).
11. Gilman JG, Huisman THJ. DNA sequence variation associated with elevated fetal G? globin production. Blood. 1985;66(4):783-787.
12. Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zincfinger protein on chromosome 2p15. Nat Genet. 2007;39(10):1197-1199.
13. Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol. 2009;145(4):455-467.
14. Bauer DE, Orkin SH. Update on fetal hemoglobin gene regulation in hemoglobinopathies. Curr Opin Pediatr. 2011;23(1):1-8.
15. Zhou D, Liu K, Sun CW, Pawlik KM, Townes TM. KLF1 regulates BCL11A expression and ?-to ?-globin gene switching. Nat Genet. 2010;42(9):742-744.
16. Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet. 2010;42(9):801-805.
17. Satta S, Perseu L, Moi P, et al. Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin. Haematologica. 2011;96 (5):767-770.
18. Perseu L, Satta S, Moi P, et al. KLF1 gene mutations cause borderline HbA(2). Blood. 2011;118 (16):4454-4458.
19. Satta S, Perseu L, Maccioni L, Giagu N, Galanello R. Delayed fetal hemoglobin switching in subjects with KLF1 gene mutation. Blood Cells Mol Dis. 2012;48(1):22-24.
20. Gallienne AE, Dréau HM, Schuh A, Old JM, Henderson S. Ten novel mutations in the erythroid transcription factor KLF1 gene associated with increased fetal hemoglobin levels in adults. Haematologica. 2012;97(3):340-343.
21. Nacoulma EW, Sawadogo D, Sakandé J, et al. Influence of fetal haemoglobin rate (FHb) on the oxidizing stress in homozygote sickle cell patient living in Abidjan, Côte-d'Ivoire. Bull Soc Pathol Exot. 2006;99(4):241-244.
22. Repka T, Hebbel RP. Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents. Blood. 1991;78(10):2753-2758.
23. Klings ES, Farber HW. Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. Respir Res. 2001;2(5):280-285.
24. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106(3):411-420.
25. Osarogiagbon UR, Choong S, Belcher JD, Vercellotti GM, Paller MS, Hebbel RP. Reperfusion injury pathophysiology in sickle transgenic mice. Blood. 2000;96(1):314-320.
26. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86(5):494-501.
27. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox Is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem. 1996;271(38):23317-23321.
28. Otterbein LE, Soares MP, Yamashita K, Bach FH. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 2003;24(8):449-455.
29. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor: Cold Spring Harbor Press, 1989.
30. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, 2011, URL http://www.R-project.org/.
31. Powars DR, Schroeder WA, Weiss JN, Chan LS, Azen SP. Lack of influence of fetal hemoglobin levels or erythrocyte indices on the severity of sickle cell anemia. J Clin Invest. 1980;65(3):732-740.
32. Serjeant GR, Richards R, Barbor PR, Milner PF. Relatively benign sickle-cell anaemia in 60 patients aged over 30 in the West Indies. Br Med J. 1968;3(5610):86-91.
33. Gilman JG, Huisman THJ. Two independent genetic factors in the ?-globin gene cluster are associated with high G?-levels in the Hb F of SS patients. Blood. 1984;64(2):452-457.
34. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBSIL-MYB, and ?-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA. 2008;105(33):11869- 11874.
35. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of ?-thalassemia. Proc Natl Acad Sci USA. 2008;105(5):1620-1625.
36. Emokpae AM, Uadia PO, Kuliya-Gwarzo A. Antioxidant enzymes and acute phase proteins correlate with marker of lipid peroxide in adult Nigerian sickle cell disease patients. Iranian J Basic Med Sci. 2010;13(4):177-182.
37. Steinberg MH. Pathophysiologically based drug treatment of sickle cell disease. Trends Pharmacol Sci. 2006;27(4):204-210.
38. Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a threshold level hemoglobin that ameliorates morbidity in sickle cell anemia? Blood. 1984;63(4):921-926.
39. Ito D, Murata M, Watanabe K, et al. C242T polymorphism of NADPH oxidase p22phox gene and ischemic cerebrovascular disease in the Japanese population. Stroke. 2000;31(4):936-939.
40. Guzik TJ, West NE, Black E, et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation. 2000;102 (15):1744-1747.
41. Nasti S, Spallarossa P, Altieri P, et al. C242T Polymorphism in CYBA gene (p22phox) and risk of coronary artery disease in a population of Caucasian Italians. Dis Markers. 2006;22(3):167-173.
42. Moreno MU, San José G, Orbe J, et al. Preliminary characterisation of the promoter of the human p22phox gene: identication of a new polymorphism associated with hypertension. FEBS Lett. 2003;542 (1-3):27-31.
43. Kokubo Y, Iwai N, Tago N, et al. Association analysis between hypertension and CYBA, CLCNKB, and KCNMB1 functional polymorphisms in the Japanese population: the Suita Study. Circ J. 2005;69 (2):138-142.
44. Lim SC, Goh SK, Lai YR, et al. Relationship between common functional polymorphisms of the p22phox gene (-930A
45. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18(6):655-673.
46. Ono K, Goto Y, Takagi S, et al. A promoter variant of the heme oxygenase-1 gene may reduce the incidence of ischemic heart disease in Japanese. Atherosclerosis. 2004;173(2):315-319.
47. Ono K, Mannami T, Iwai N. Association of a promoter variant of the haeme oxygenase-1 gene with hypertension in women. J Hypertens. 2003;21(8):1497-1503.
48. Rueda B, Oliver J, Robledo G, et al. HO-1 promoter polymorphism associated with rheumatoid arthritis. Arthritis Rheum. 2007;56(12):3953-3958.
49. Cao YA, Kusy S, Luong R, Wong RJ, Stevenson DK, Contag CH. Heme oxygenase-1 deletion affects stress erythropoiesis. PLoS One. 2011;6(5):e20634. Estado de São Paulo